Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, traditional-Chinese medicine maker American Oriental Bioengineering (NYSE:AOB) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at AOB's business, and see what CAPS investors are saying about the stock right now.

AOB facts

Headquarters (founded)

Shenzhen, China (2003)

Market Cap

$392.03 million

Industry

Biotechnology

TTM Revenue

$264.64 million

Management

Chairman/CEO Shujun Liu

Co-Founder/CFO Yanchun Li

Compound Annual Revenue Growth (over last five years)

66.2%

Competitors

Harbin Pharmaceutical

Fosun International

CAPS members bullish on AOB also bullish on

Apple (NASDAQ:AAPL)

General Electric (NYSE:GE)

Cemex (NYSE:CX)

CAPS members bearish on AOB also bearish on

InterOil (NYSE:IOC)

Vonage Holdings (NYSE:VG)

First Solar (NASDAQ:FSLR)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, fully 2,706 of the 2,779 members who have rated AOB -- some 97% -- believe the stock will outperform the S&P 500 going forward. These bulls include mrfett and All-Star MattMcComb, who is ranked in the top 20% of our community.

Last month, mrfett tapped AOB as an ancient method of curing portfolio sickness:

Traditional remedies are increasingly becoming mainstream. China is risky for myriad reasons, but this stock seems heavily discounted. It's no secret that China is a massive market, and this company should be well positioned for growth.

In a pitch from earlier in the month, MattMcComb can't help but run with the Foolish herd:

Another bandwagon pick. I know this company is incredibly popular in the Fool community, but I think it's with good reason. Health care is a recession-resistant field in general, and a fast-growing one in China as rising incomes allow more Chinese people to be able to afford AOB's products. Valuation is extremely reasonable, more than discounting what I see as a minimal management risk (the dodginess with the large conference building).

What do you think about AOB, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 130,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. AOB is a Motley Fool Hidden Gems and Global Gains pick. Cemex is a Stock Advisor and Global Gains choice. Apple is also a selection of Stock Advisor. The Fool owns shares of AOB and Cemex. The Fool's disclosure policy always gets a perfect score.